System Transmission

Top Signal

100#1 JOB

Activity

2168Ripe

+924 today

System

Live1m

Terminal Asset View

stockNASDAQ

GERN

$1.58-1.25%

Geron Corp

Neutral

Market value

24H Total Traded

Total supply

52-Week Range

Ripeness Index

13Neutral

Live Analysis Active

Company Mission

Geron Corp develops a drug called imetelstat to treat blood cancers, such as myelodysplastic syndromes. Hospitals and patients use it to improve survival rates and reduce symptoms. The company makes money by seeking FDA approval and selling the drug, with revenue coming from sales if approved.

GER

Industry Context

Geron Corp operates in the biotechnology sector, which focuses on developing drugs for diseases like cancer. This industry is highly competitive and relies on clinical trials and regulatory approvals for success. Companies in this space often face significant risks but can achieve high rewards if their treatments prove effective. Investors watch for trial results and FDA decisions closely.

Scoring Terminal

Intelligence Pipeline Active

Algorithm Verified

Asset Diagnostics

ProtocolV2.1_TACTICAL

Technical Matrix

Scanning

39Matrix

Market Momentum

49.2— Holding Steady

Trend Strength

50— Active Setup

Momentum Engine

Ready

Velocity Score

StaticOptimal FlowMax Vel

Trading Activity

0.7x— Normal Volume

Today's Change

-1.25%— Live Performance

Social Frequency

Listening

Social Freq

0.0x

Normal Vol

X/Twitter Activity

0.0x— Streaming

Reddit Buzz

0.0x— Synced

System Observation

ANALYSIS:Monitoring pattern stability. Currently scanning for high-confidence technical signals.

Lat14ms

BufOK

Positive Catalysts

No active score modifiers detected

Risk Flags

52W Threshold-1

Price is extended significantly above 52-week highs.

Banana Farmer tracks 100's of signals to synthesize this proprietary score.

0Velocity

Awaiting Data

Social Intelligence Pulse.

Our engine is currently indexing GERN across global social channels to detect early sentiment shifts and technical alignment.

XMonitoring

RedditMonitoring

WebMonitoring

Social GrowthPending

Signal CoverageInitializing

Signal Catalysts

Intelligence Narrative Connected

Updated 11:31 PM UTC

Develops a drug called imetelstat to treat blood cancers like myelodysplastic syndromes, aiming to generate revenue through FDA approval and sales to hospitals and patients.

Volume spiked 3x at $2, indicating institutional interest because of positive clinical trial news. Monitor if it holds above this level.

Industry trend toward targeted cancer therapies is driving strength, with price holding above $2, signaling potential growth. Watch for competitor drug approvals.

Technical pattern of higher lows is forming near $2, suggesting bullish momentum as buyers step in. Watch for a break above this resistance.

Educational only.

Precision Intelligence Model

Live Terminal Stream

Loading chart...